• Wiley Online Library will be disrupted on 26 May from 10:00-12:00 BST (05:00-07:00 EDT) for essential maintenance

Original Article

You have full text access to this OnlineOpen article

Increased prevalence of bisphosphonate-related osteonecrosis of the jaw with vitamin D deficiency in rats

  1. Akishige Hokugo1,
  2. Russell Christensen2,
  3. Evelyn M Chung1,3,
  4. Eric C Sung1,3,
  5. Alan L Felsenfeld4,
  6. James W Sayre5,
  7. Neal Garrett1,
  8. John S Adams6,
  9. Ichiro Nishimura1,*

Article first published online: 14 JAN 2010

DOI: 10.1002/jbmr.23

Issue

Journal of Bone and Mineral Research

Journal of Bone and Mineral Research

Volume 25, Issue 6, pages 1337–1349, June 2010

Additional Information

How to Cite

Hokugo, A., Christensen, R., Chung, E. M., Sung, E. C., Felsenfeld, A. L., Sayre, J. W., Garrett, N., Adams, J. S. and Nishimura, I. (2010), Increased prevalence of bisphosphonate-related osteonecrosis of the jaw with vitamin D deficiency in rats. J Bone Miner Res, 25: 1337–1349. doi: 10.1002/jbmr.23

Author Information

  1. 1

    The Jane and Jerry Weintraub Center for Reconstructive Biotechnology, UCLA School of Dentistry, Los Angeles, CA, USA

  2. 2

    Section of Oral and Maxillofacial Pathology, UCLA School of Dentistry, Los Angeles, CA, USA

  3. 3

    Section of Hospital Dentistry, UCLA School of Dentistry, Los Angeles, CA, USA

  4. 4

    Section of Oral and Maxillofacial Surgery, UCLA School of Dentistry, Los Angeles, CA, USA

  5. 5

    Department of Biostatistics, UCLA School of Public Health, Los Angeles, CA, USA

  6. 6

    The Orthopedic Hospital Musculoskeletal Research Institute, The David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

*The Weintraub Center for Reconstructive Biotechnology, UCLA School of Dentistry, Box 951668, CHS B3-087, Los Angeles, CA 90095-1668, USA.

Publication History

  1. Issue published online: 27 MAY 2010
  2. Article first published online: 14 JAN 2010
  3. Accepted manuscript online: 14 JAN 2010 12:00AM EST
  4. Manuscript Accepted: 29 DEC 2009
  5. Manuscript Revised: 9 NOV 2009
  6. Manuscript Received: 8 APR 2009

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (409K)

References

  • 1
    Berenson JR, Lipton A. Bisphosphonates in the treatment of malignant bone disease. Annu Rev Med. 1999; 50: 237–248.
  • 2
    Tanvetyanon T, Stiff PJ. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol. 2006; 17: 897–907.
  • 3
    Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003; 61: 1115–1117.
  • 4
    Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004; 62: 527–534.
  • 5
    Woo SB, Hellstein JW, Kalmar JR. Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006; 144: 753–761.
  • 6
    Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol. 2005; 23: 8580–8587.
  • 7
    Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med. 2005; 353: 99–102.
  • 8
    Ruggiero SL, Drew SJ. Osteonecrosis of the jaws and bisphosphonate therapy. J Dent Res. 2007; 86: 1013–1021.
  • 9
    Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005; 63: 1567–1575.
  • 10
    Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007; 22: 1479–1491.
    Direct Link:
  • 11
    Marx RE, Cillo JE, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg. 2007; 65: 2397–2410.
  • 12
    Kyrgidis A, Vahtsevanos K, Koloutsos G, et al. Bisphosphonate-related osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients. J Clin Oncol. 2008; 26: 4634–4638.
  • 13
    Sonis ST, Watkins BA, Lyng GD, Lerman MA, Anderson KC. Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients. Oral Oncol. 2009; 45: 164–172.
  • 14
    Reid IR. Osteonecrosis of the jaw: who gets it, and why? Bone. 2009; 44: 4–10.
  • 15
    Badros A, Goloubeva O, Terpos E, Milliron T, Baer MR, Streeten E. Prevalence and significance of vitamin D deficiency in multiple myeloma patients. Br J Haematol. 2008.
    Direct Link:
  • 16
    Lowe LC, Guy M, Mansi JL, et al. Plasma 25-hydroxy vitamin D concentrations, vitamin D receptor genotype and breast cancer risk in a UK Caucasian population. Eur J Cancer. 2005; 41: 1164–1169.
  • 17
    Ardine M, Generali D, Donadio M, et al. Could the long-term persistence of low serum calcium levels and high serum parathyroid hormone levels during bisphosphonate treatment predispose metastatic breast cancer patients to undergo osteonecrosis of the jaw? Ann Oncol. 2006; 17: 1336–1337.
  • 18
    Lehrer S, Montazem A, Ramanathan L, et al. Normal serum bone markers in bisphosphonate-induced osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008; 106: 389–391.
  • 19
    Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J. 2001; 7: 377–387.
  • 20
    Sukotjo C, Lin A, Song K, Ogawa T, Wu B, Nishimura I. Oral fibroblast expression of wound-inducible transcript 3.0 (wit3.0) accelerates the collagen gel contraction in vitro. J Biol Chem. 2003; 278: 51527–51534.
  • 21
    Haber M. An exact unconditional test for the 2×2 comparative trial. Psychometrics Bull. 1986; 99: 129–132.
  • 22
    Turner RT, Evans GL, Lotinun S, Lapke PD, Iwaniec UT, Morey-Holton E. Dose-response effects of intermittent PTH on cancellous bone in hindlimb unloaded rats. J Bone Miner Res. 2007; 22: 64–71.
    Direct Link:
  • 23
    Chatziiannou A, Qi J, Moore A, et al. Comparison of 3-D maximum a posterior and filtered backprojection algorithms for high-resolution animal imaging with microPET. IEEE Trans Med Imaging. 2000; 19: 507–512.
  • 24
    Hansen T, Kunkel M, Weber A, James Kirkpatrick C. Osteonecrosis of the jaws in patients treated with bisphosphonates: histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med. 2006; 35: 155–160.
    Direct Link:
  • 25
    Surgeons AAoOaM. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007; 65: 369–376.
  • 26
    Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007; 22: 1479–1491.
    Direct Link:
  • 27
    Nishimura I, Damiani PJ, Atwood DA. Resorption of residual ridges (RRR) in rats. J Dent Res. 1987; 66: 1753–1757.
  • 28
    Hsieh YD, Devlin H, Roberts C. Early alveolar ridge osteogenesis following tooth extraction in the rat. Arch Oral Biol. 1994; 39: 425–428.
  • 29
    Stratis A, Pasparakis M, Markur D, et al. Localized inflammatory skin disease following inducible ablation of IκB kinase 2 in murine epidermis. J Invest Dermatol. 2006; 126: 614–620.
  • 30
    Warter A, Walter P, Meyer C, Barriere P, Galatir L, Wilk A. Mandibular pseudocarcinomatous hyperplasia. Histopathology. 2000; 37: 115–117.
    Direct Link:
  • 31
    Akilov OE, Donovan MJ, Stepinac T, et al. T helper type 1 cytokines and keratinocyte growth factor play a critical role in pseudoepitheliomatous hyperplasia initiation during cutaneous leishmaniasis. Arch Dermatol Res. 2007; 299: 315–325.
  • 32
    Croucher PI, De Hendrik R, Perry MJ, et al. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res. 2003; 18: 482–492.
    Direct Link:
  • 33
    Gasser JA, Ingold P, Venturiere A, Shen V, Green JR. Long-term protective effects of zoledronic acid on cancellous and cortical bone in the ovariectomized rat. J Bone Miner Res. 2008; 23: 544–551.
    Direct Link:
  • 34
    Bitto A, Burnett BP, Polito F, et al. Effects of genistein aglycone in osteoporotic, ovariectomized rats: a comparison with alendronate, raloxifene and oestradiol. Br J Pharmacol. 2008; 155: 896–905.
    Direct Link:
  • 35
    Diaz-Curiel M, de la Piedra C, Romero FI, et al. Effect of risedronate on bone mass, remodelling and biomechanical strength in orchidectomized rats. Horm Res. 2008; 70: 93–99.
  • 36
    Nishimura I, Hosokawa R, Atwood DA. The knife-edge tendency in mandibular residual ridges in women. J Prosthet Dent. 1992; 67: 820–826.
  • 37
    Anderson PH, Sawyer RK, Moore AJ, May BK, O'Loughlin PD, Morris HA. Vitamin D depletion induces RANKL-mediated osteoclastogenesis and bone loss in a rodent model. J Bone Miner Res. 2008; 23: 1789–1797.
    Direct Link:
  • 38
    Nehme D, Rondeau E, Paillard F, et al. Aseptic necrosis of bone following renal transplantation: relation with hyperparathyroidism. Nephrol Dial Transplant. 1989; 4: 123–128.
  • 39
    Raje N, Woo SB, Hande K, et al. Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw. Clin Cancer Res. 2008; 14: 2387–2395.
  • 40
    Jahangiri L, Devlin H, Ting K, Nishimura I. Current perspectives in residual ridge remodeling and its clinical implications: a review. J Prosthet Dent. 1998; 80: 224–237.
  • 41
    Devlin H. Early bone healing events following rat molar tooth extraction. Cells Tissues Organs. 2000; 167: 33–37.
  • 42
    Hakim SG, Bruecker CW, Jacobsen H, et al. The value of FDG-PET and bone scintigraphy with SPECT in the primary diagnosis and follow-up of patients with chronic osteomyelitis of the mandible. Int J Oral Maxillofac Surg. 2006; 35: 809–816.
  • 43
    Liu PT, Stenger S, Li H, et al. Toll-like receptor triggering of a vitamin D–mediated human antimicrobial response. Science. 2006; 311: 1770–1773.
  • 44
    Gombart AF, Borregaard N, Koeffler HP. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3. FASEB J. 2005; 19: 1067–1077.
  • 45
    Adams JS, Gacad MA. Characterization of 1 alpha-hydroxylation of vitamin D3 sterols by cultured alveolar macrophages from patients with sarcoidosis. J Exp Med. 1985; 161: 755–765.
  • 46
    Adams JS, Hewison M. Unexpected actions of vitamin D: new perspectives on the regulation of innate and adaptive immunity. Nat Clin Pract Endocrinol Metab. 2008; 4: 80–90.
  • 47
    Roelofs AJ, Thompson K, Gordon S, Rogers MJ. Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res. 2006; 12: 6222s–6230s.
  • 48
    Russell RG, Xia Z, Dunford JE, et al. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann NY Acad Sci. 2007; 1117: 209–257.
    Direct Link:
  • 49
    Roelofs AJ, Jauhiainen M, Monkkonen H, Rogers MJ, Monkkonen J, Thompson K. Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP. Br J Haematol. 2009; 144: 245–250.
    Direct Link:
  • 50
    Otten K, Wang HC, Wyde PR, Klein JR. Modulation of γδ T cells in mouse buccal epithelium following antigen priming. Biochem Biophys Res Commun. 2002; 294: 626–629.
  • 51
    Mathur A, Michalowicz BS. Cell-mediated immune system regulation in periodontal diseases. Crit Rev Oral Biol Med. 1997; 8: 76–89.
  • 52
    Chen L, Cencioni MT, Angelini DF, Borsellino G, Battistini L, Brosnan CF. Transcriptional profiling of γδ T cells identifies a role for vitamin D in the immunoregulation of the Vγ9Vδ2 response to phosphate-containing ligands. J Immunol. 2005; 174: 6144–6152.
  • 53
    Cipriani B, Borsellino G, Poccia F, et al. Activation of C—C β-chemokines in human peripheral blood gammadelta T cells by isopentenyl pyrophosphate and regulation by cytokines. Blood. 2000; 95: 39–47.
  • 54
    Ramos CD, Canetti C, Souto JT, et al. MIP-1α[CCL3] acting on the CCR1 receptor mediates neutrophil migration in immune inflammation via sequential release of TNF-α and LTB4. J Leukoc Biol. 2005; 78: 167–177.
  • 55
    Chin AC, Lee WY, Nusrat A, Vergnolle N, Parkos CA. Neutrophil-mediated activation of epithelial protease-activated receptors-1 and -2 regulates barrier function and transepithelial migration. J Immunol. 2008; 181: 5702–5710.
  • 56
    Muraro M, Mereuta OM, Carraro F, Madon E, Fagioli F. Osteosarcoma cell line growth inhibition by zoledronate-stimulated effector cells. Cell Immunol. 2007; 249: 63–72.
View Full Article (HTML) Get PDF (409K)